{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:51:44Z","timestamp":1791373904524,"version":"4.3.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00120-026-02918-0","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:08:02Z","timestamp":1789114082000},"page":"1103-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update Nierenzellkarzinom","Update renal cell carcinoma"],"prefix":"10.1007","volume":"65","author":[{"given":"Philip","family":"Zeuschner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Stolzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2918_CR1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2025.0203","author":"A Silvestri","year":"2025","unstructured":"Silvestri\u00a0A, Gavi\u00a0F, Sighinolfi\u00a0MC, Assumma\u00a0S, Panio\u00a0E, Fettucciari\u00a0D et\u00a0al (2025) Management of Small Renal Masses: Literature and Guidelines Review. Int Braz J Urol. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2025.0203","journal-title":"Int Braz J Urol"},{"issue":"5","key":"2918_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MOU.0b013e328355ecdf","volume":"22","author":"BR Lane","year":"2012","unstructured":"Lane\u00a0BR, Tobert\u00a0CM, Riedinger\u00a0CB (2012) Growth kinetics and active surveillance for small renal masses. Curr Opin Urol 22(5):353\u2013359. https:\/\/doi.org\/10.1097\/MOU.0b013e328355ecdf","journal-title":"Curr Opin Urol"},{"issue":"3","key":"2918_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.eururo.2020.06.053","volume":"78","author":"A Finelli","year":"2020","unstructured":"Finelli\u00a0A, Cheung\u00a0DC, Al-Matar\u00a0A, Evans\u00a0AJ, Morash\u00a0CG, Pautler\u00a0SE et\u00a0al (2020) Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. Eur Urol Oncol 78(3):460\u2013467. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.053","journal-title":"Eur Urol"},{"issue":"6","key":"2918_CR4","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00345-020-03283-z","volume":"40","author":"JC Bernhard","year":"2022","unstructured":"Bernhard\u00a0JC, Robert\u00a0G, Ricard\u00a0S, Michiels\u00a0C, Capon\u00a0G, Boulenger de Hautecloque\u00a0A et\u00a0al (2022) Day-case robotic-assisted partial nephrectomy: feasibility and preliminary results of a prospective evaluation (UroCCR-25 AMBU-REIN study). World J Urol 40(6):1351\u20131357. https:\/\/doi.org\/10.1007\/s00345-020-03283-z","journal-title":"World J Urol"},{"issue":"1","key":"2918_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.juro.2007.08.124","volume":"179","author":"BR Lane","year":"2008","unstructured":"Lane\u00a0BR, Samplaski\u00a0MK, Herts\u00a0BR, Zhou\u00a0M, Novick\u00a0AC, Campbell\u00a0SC (2008) Renal mass biopsy--a renaissance? J\u00a0Urol 179(1):20\u201327. https:\/\/doi.org\/10.1016\/j.juro.2007.08.124","journal-title":"J Urol"},{"issue":"3","key":"2918_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.eururo.2015.02.001","volume":"68","author":"PM Pierorazio","year":"2015","unstructured":"Pierorazio\u00a0PM, Johnson\u00a0MH, Ball\u00a0MW, Gorin\u00a0MA, Trock\u00a0BJ, Chang\u00a0P et\u00a0al (2015) Five-year analysis of a\u00a0multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol Oncol 68(3):408\u2013415. https:\/\/doi.org\/10.1016\/j.eururo.2015.02.001","journal-title":"Eur Urol"},{"issue":"Supplement\u00a04","key":"2918_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000932.010","volume":"203","author":"J Cheaib","year":"2020","unstructured":"Cheaib\u00a0J, Alam\u00a0R, Kassiri\u00a0B, Biles\u00a0M, Metcalf\u00a0M, Wlajnitz\u00a0T, Wagner\u00a0A, Chang\u00a0P, Johnson\u00a0M, McKiernan\u00a0J, Allaf\u00a0M, Pierorazio\u00a0P (2020) PD45-10\u00a0ACTIVE SURVEILLANCE FOR SMALL RENAL MASSES IS SAFE AND NON-INFERIOR: 10-YEAR UPDATE FROM THE DISSRM REGISTRY. J\u00a0Urol 203(Supplement\u00a04):e917. https:\/\/doi.org\/10.1097\/JU.0000000000000932.010","journal-title":"J Urol"},{"issue":"5","key":"2918_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","volume":"32","author":"B Shuch","year":"2014","unstructured":"Shuch\u00a0B, Vourganti\u00a0S, Ricketts\u00a0CJ, Middleton\u00a0L, Peterson\u00a0J, Merino\u00a0MJ et\u00a0al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J\u00a0Clin Oncol 32(5):431\u2013437. https:\/\/doi.org\/10.1200\/JCO.2013.50.8192","journal-title":"J Clin Oncol"},{"issue":"8","key":"2918_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Tomczak\u00a0P, Park\u00a0SH, Venugopal\u00a0B, Ferguson\u00a0T, Chang\u00a0YH et\u00a0al (2021) Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 385(8):683\u2013694. https:\/\/doi.org\/10.1056\/NEJMoa2106391","journal-title":"N Engl J Med"},{"key":"2918_CR10","doi-asserted-by":"publisher","DOI":"10.1159\/000543278","author":"A Mattigk","year":"2024","unstructured":"Mattigk\u00a0A, Cano Garcia\u00a0C, Klumper\u00a0N, Cox\u00a0A, Hahn\u00a0O, Junker\u00a0K et\u00a0al (2024) Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort. Urol Int. https:\/\/doi.org\/10.1159\/000543278","journal-title":"Urol Int"},{"key":"2918_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.007","author":"BI Rini","year":"2025","unstructured":"Rini\u00a0BI, Albiges\u00a0L, Tang\u00a0X, Koeppen\u00a0H, Bex\u00a0A, Suarez\u00a0C et\u00a0al (2025) Circulating kidney injury molecule\u20111 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.007","journal-title":"Ann Oncol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02918-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:09:46Z","timestamp":1791371386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02918-0"}},"subtitle":["Leitlinien-Update \u201esmall renal masses\u201c","Guideline update on small renal masses"],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2918"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02918-0","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Zeuschner\n                      : A.\u00a0Finanzielle Interessen: Intuitive Surgical: Forschungsprojekt zur Kostenanalyse von Nierenteilresektionen. \u2013\u00a0Vortragshonorare: Janssen, Meda, MSD, Ipsen, Recordati, AstraZeneca, Ad Board: Apogepha, Kongressfinanzierung: Ipsen, Medac, Bayer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Gesch\u00e4ftsf\u00fchrender Oberarzt, Klinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum des Saarlandes | Keine f\u00fcr diesen Vortrag relevante Mitgliedschaften.\n                      S.\u00a0Siemer\n                      : A.\u00a0Finanzielle Interessen: Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Proctor f\u00fcr Intuitive Surgical System. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: UKS, Klinik f\u00fcr Urologie und Kinderurologie, Kommissarischer Leiter der Klinik f\u00fcr Urologie und Kinderurologie | Mitgliedschaften: DGU | SWDGU | DKG | DGRU | AUO.\n                      J.-U.\u00a0Stolzenburg\n                      : A.\u00a0Finanzielle Interessen: J.-U. Stolzenburg gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor Klinik und Poliklinik f\u00fcr Urologie, Universit\u00e4tsklinikum Leipzig | Vorstandsmitglied der Deutschen Gesellschaft f\u00fcr Urologie, Pr\u00e4sident S\u00e4chsische Gesellschaft f\u00fcr Urologie.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}